HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infestation by Sarcoptes — Clinical Guidelines

Overview

Sarcoptic mange, caused by the burrowing mite Sarcoptes scabiei, is a highly contagious and debilitating ectoparasitic disease affecting a wide range of mammals, including rabbits, dogs, and humans. In rabbits (Oryctolagus cuniculus), it manifests as severe dermatological lesions characterized by crusted, hyperkeratotic lesions primarily on the head, face, and limbs, leading to significant physiological stress, reduced growth performance, and substantial economic losses due to decreased productivity and reproduction rates. Clinicians must recognize and manage this condition promptly to mitigate clinical signs and prevent widespread infestation within populations. Early intervention is crucial for improving animal welfare and productivity in affected species 1 2.

Pathophysiology

The pathophysiology of sarcoptic mange involves complex interactions at the molecular, cellular, and tissue levels. Sarcoptes scabiei mites burrow into the epidermis, inducing intense pruritus and triggering a robust host immune response. This immune reaction includes the activation of mast cells and the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), contributing to inflammation and tissue damage 1. The mites feed on epidermal cells, leading to epidermal hyperplasia and hyperkeratosis, which are hallmarks of the clinical lesions observed. Additionally, oxidative stress is elevated, as evidenced by increased activities of antioxidant enzymes like superoxide dismutase (SOD) and glutathione peroxidase (GPx), reflecting the host's attempt to counteract the inflammatory and cytotoxic effects of the infestation 1. These processes collectively result in the characteristic clinical manifestations and systemic impacts on affected animals.

Epidemiology

The incidence and prevalence of sarcoptic mange vary significantly by species and geographic region. In rabbits, particularly in intensive farming settings in regions like Egypt, the disease is prevalent, affecting weaner rabbits predominantly during specific seasons (e.g., May to November) 1. In wildlife, such as coyotes, red foxes, and American black bears, sarcoptic mange has been increasingly reported in certain areas of North America, suggesting potential shifts in endemic patterns 3. Risk factors include overcrowding, poor hygiene, and close contact among animals, which facilitate transmission. While specific incidence rates are not universally standardized, the disease's impact underscores the need for vigilant surveillance and control measures in both domestic and wild populations 1 3.

Clinical Presentation

Clinical signs of sarcoptic mange in rabbits include characteristic crusted, hyperkeratotic lesions primarily on the head, face, and limbs, accompanied by intense pruritus leading to self-trauma and secondary infections. Affected animals often exhibit reduced body weight gain, decreased feed consumption, and poor feed conversion efficiency. In atypical presentations, lesions may be less pronounced or localized differently, potentially complicating early diagnosis. Red-flag features include severe alopecia, significant weight loss, and systemic signs of distress, which necessitate prompt veterinary intervention 1.

Diagnosis

Diagnosis of sarcoptic mange involves a combination of clinical assessment and confirmatory tests. Clinicians should observe characteristic skin lesions and conduct a thorough physical examination. Key diagnostic criteria include:

Clinical Signs: Presence of crusted, hyperkeratotic lesions, particularly on the head, face, and limbs, with evidence of pruritus.

Parasitological Examination: Skin scrapings or biopsies analyzed microscopically for Sarcoptes scabiei mites or eggs. Punch biopsies can provide higher accuracy in quantifying mite burden 3.

Histopathological Analysis: Examination of skin biopsies showing epidermal hyperkeratosis, mast cell infiltration, and inflammatory cell accumulations.

Immunological Markers: Elevated levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and oxidative stress markers (SOD, GPx) in affected tissues can support the diagnosis 1.

Differential Diagnosis:

Atopic Dermatitis: Typically lacks the characteristic burrowing mites and may present with different distribution patterns of lesions.

Folliculitis or Bacterial Infections: Secondary infections can mimic mange but usually respond differently to antimicrobial therapy.

Nutritional Deficiencies: Can cause skin lesions but without the specific mite involvement evident in mange 1.

Management

First-Line Treatment

Ivermectin: Administered subcutaneously (1.5 mg/kg) and topically (0.1% solution), repeated every 14 days for two treatments. Effective in eliminating mites and improving growth performance 2.

Imidacloprid + Moxidectin: Spot-on formulation (Advocate/Advantage Multi) applied topically as per label instructions, demonstrating high efficacy in dogs with 100% parasitological cure rates 4.

Monitoring:

Regular clinical assessments for resolution of lesions and improvement in growth parameters.

Parasitological re-evaluation post-treatment to confirm eradication.

Second-Line Treatment

Naringin (NG) and Naringin Nanoformulation (NGNPs): Used in combination with ivermectin to enhance efficacy, particularly in refractory cases. Oral administration at 7.5 mg/kg/day for 28 days 2.

Alternative Acaricides: Consider selamectin or other approved acaricides if primary treatments fail, ensuring adherence to dosing guidelines and monitoring for adverse effects.

Contraindications:

Avoid use in animals with known hypersensitivity to the active ingredients.

Careful assessment of concurrent medications to prevent interactions.

Complications

Secondary Infections: Bacterial or fungal infections secondary to skin lesions, requiring targeted antimicrobial or antifungal therapy.

Systemic Illness: Severe cases may lead to systemic illness due to chronic stress and malnutrition, necessitating supportive care including fluid therapy and nutritional supplementation.

Refractory Cases: Persistent infestation despite treatment may indicate resistance or inadequate dosing, warranting referral to a specialist for advanced management strategies 1 2.

Prognosis & Follow-Up

The prognosis for sarcoptic mange is generally good with timely and appropriate treatment. Key prognostic indicators include early diagnosis, adherence to treatment protocols, and absence of complications. Follow-up should include:

Clinical Monitoring: Regular assessments every 2-4 weeks post-treatment to ensure lesion resolution and sustained clinical improvement.

Parasitological Re-evaluation: Skin scrapings or biopsies at 4-6 weeks post-treatment to confirm eradication of mites.

Growth Performance: Monitoring body weight and feed conversion efficiency to assess recovery in productivity 1.

Special Populations

Rabbits (Pediatric and Adult): Young rabbits are particularly vulnerable due to their rapid growth requirements; early intervention is crucial to prevent long-term developmental impacts 1.

Dogs with Comorbidities: Animals with concurrent dermatological or systemic conditions may require tailored treatment plans to manage multiple health issues simultaneously 4.

Key Recommendations

Early Diagnosis and Treatment: Implement regular screening for clinical signs and confirmatory tests to diagnose sarcoptic mange early (Evidence: Strong 1 2).

Use of Ivermectin: Employ subcutaneous and topical ivermectin as first-line therapy, ensuring appropriate dosing and follow-up (Evidence: Strong 2 4).

Combination Therapies: Consider combining ivermectin with naringin or its nanoformulation for enhanced efficacy in refractory cases (Evidence: Moderate 2).

Monitor Growth Parameters: Regularly assess growth performance indices such as body weight gain and feed conversion efficiency post-treatment (Evidence: Moderate 1).

Supportive Care: Provide supportive care including nutritional support and monitoring for secondary infections (Evidence: Expert opinion).

Referral for Refractory Cases: Refer cases showing resistance or persistent infestation to specialists for advanced management strategies (Evidence: Expert opinion).

Control Measures: Implement strict hygiene protocols and isolate affected animals to prevent spread within populations (Evidence: Moderate 1).

Follow-Up Assessments: Schedule follow-up evaluations at 4-6 weeks post-treatment to confirm eradication and monitor recovery (Evidence: Moderate 1).

Consider Geographic Risk: Tailor surveillance efforts based on known endemic regions and risk factors for specific populations (Evidence: Moderate 3).

Educate Owners: Provide comprehensive guidance to owners on recognizing signs and adhering to treatment regimens to ensure compliance (Evidence: Expert opinion).

References

1 Attia MM, Sobhi BM, Elaish M, El-Saied MA, Mousa MR, El-Gameel SM. Significant Sarcoptes scabiei infestation in rabbits (Oryctolagus cuniculus): effects on physiological, apoptotic, histological, immunohistochemical, and growth performance indices. Veterinary parasitology, regional studies and reports 2026. link 2 Hassanen EI, Sherif AA, Eldin ZE, Abuowarda M, Ibrahim MA, Doghaim R. Innovative naringin-ivermectin combination for improved scabies management and dermal healing in rabbits. Veterinary parasitology 2026. link 3 Tiffin HS, Cockerill R, Brown JD, Machtinger ET. A Tissue Digestion Protocol for Measuring Sarcoptes scabiei (Astigmata: Sarcoptidae) Density in Skin Biopsies. Journal of insect science (Online) 2020. link 4 Krieger K, Heine J, Dumont P, Hellmann K. Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study. Parasitology research 2005. link

Infestation by Sarcoptes